Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 12,477 shares of the company’s stock after selling 207 shares during the period. Amalgamated Bank’s holdings in Medpace were worth $4,145,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Iron Triangle Partners LP acquired a new stake in Medpace in the third quarter valued at approximately $64,371,000. Wellington Management Group LLP lifted its position in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares in the last quarter. DF Dent & Co. Inc. grew its stake in Medpace by 189.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after acquiring an additional 105,659 shares during the period. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Medpace in the 3rd quarter worth $23,321,000. Finally, Swedbank AB raised its position in Medpace by 245.5% during the fourth quarter. Swedbank AB now owns 77,400 shares of the company’s stock worth $25,715,000 after acquiring an additional 55,000 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.4 %

MEDP opened at $327.32 on Friday. The firm has a market capitalization of $9.97 billion, a PE ratio of 25.92, a PEG ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The firm’s 50-day moving average price is $342.66 and its 200 day moving average price is $345.71.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.